Action INVA INNOVIVA, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Innoviva, Inc.

Actions

INVA

US45781M1018

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 18/06/2024 		Varia. 5j. Varia. 1 janv.
16,22 USD +0,37 % Graphique intraday de Innoviva, Inc. +2,01 % +1,12 %
14:01 INNOVIVA, INC. : Opinion positive de Cantor Fitzgerald ZM
10/06 Transcript : Innoviva, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 01:20 PM

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BU
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
AQ
Innoviva : Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam Durlobactam or SUL DUR) for Hospital Acquired and Ventilator Associated Pneumonia Caused by Acinetobacter Baumannii Calcoaceticus Complex in China
PU
Innoviva: Q1 Earnings Snapshot
AQ
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
BU
Innoviva to Participate in the BofA Securities Health Care Conference
BU
Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
AQ
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
BU
Innoviva: Q4 Earnings Snapshot
AQ
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
BU
Innoviva Specialty Therapeutics Appoints David Altarac, MD, as Chief Medical Officer
AQ
Innoviva Specialty Therapeutics - Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
AQ
Innoviva: Q3 Earnings Snapshot
AQ
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
BU
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
BU
Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week 2023
AQ
Innoviva to Participate in the Cantor Global Healthcare Conference
BU
Innoviva - XACDURO, the First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia in Adults
AQ
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
BU
Innoviva Appoints Stephen Basso as Chief Financial Officer
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action INVA
  4. Actualités Innoviva, Inc.
  5. Communiqués